Lilly Strikes $1B+ AI-Powered Oligonucleotide Deal with Creyon Bio

4Month29Day,Creyon BioAnnounced a global licensing and multi-target research collaboration with Eli Lilly, jointly focusing on innovative targeted therapies.RNAThe Discovery, Development, and Commercialization of Oligonucleotide Therapies in Various Diseases.CreyonWill leverage its uniqueAIDrive the oligonucleotide engineering engine to design and optimize candidate compounds for Eli Lilly's specified targets.

According to the terms of the agreement,CreyonWill Obtain1300Million USD upfront payment, and upon reaching specific milestones, is eligible to receive over10Hundreds of millions of dollars in R&D and commercialization payments. Lilly obtains exclusive licenses for lead drug candidates based on various targets, and after achieving relevant milestones, assumes responsibility for subsequent research, development, and commercialization.

CreyonCreyon Bio is a company focused on the research and development of nucleic acid drugs, committed to developing safer and more effective oligonucleotide therapies aimed at treating both rare and common diseases. The company will develop tissue-specific therapies by combining proprietary computational methods with aptamer-based tissue-specific delivery approaches.RNATargeted oligonucleotide therapy.

CreyonEstablished the industry's firstAIA driven oligonucleotide engineering engine capable of designing safe and effective oligonucleotides in a more systematic and cost-effective manner, surpassing traditional methods.

Modular Building Blocks for Precision Drug Design (Source: Company Official Website)

This is not Lilly's first foray into the oligonucleotide field:

2024Year9Month,Lilly &Genetic LeapReach Cooperation, will utilizeGenetic LeapTheRNATargeted drugsAIPlatform to develop oligonucleotide drugs for targets selected by Eli Lilly.Genetic LeapWill have the opportunity to receive up to4.09Total payment in billions of dollars.

2024Year6Month,Lilly Announces Collaboration withQurAlisCooperation，QurAlisGranting Lilly Development and CommercializationQRL-204Global rights.QRL-204Is a potentialfirst-in-classSplicing Switch (splice-switching）Antisense Oligonucleotide, aiming to restore Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD）and other neurodegenerative diseases中的UNC13AFunction.QurAlisWill Obtain4500Million USD upfront payment, with eligibility for up to5.77USD billion in milestone payments.

CreyonChairman and Chief Executive OfficerSerge MesserlianSaid: "We are delighted to collaborate with Eli Lilly to advance our designed approach based onAIOligonucleotide therapy. This collaboration marksCreyonAn important milestone for the company, as we are working hard to address both rare and common diseases.RNACreyon Bio's targeted oligonucleotide therapy pipeline advances to the clinical trial stage.”

References:

[1]https://creyonbio.com/latest-news/

[2]https://www.fiercebiotech.com/biotech/eli-lilly-pens-creyon-bio-ai-oligonucleotide-pact-1b-biobucks-table

PharmaCube Pro

Insight into Global Biomedical Frontiers Trends

Empowering the Transformation of China's Indigenous Innovation Achievements

Media cooperation: 15895423126